REFERENCES
- Government of Canada. Asthma and Chronic Obstructive Pulmonary Disease (COPD) in Canada, 2018. Report from the Canadian Chronic Disease Surveillance System. Available from: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/asthma-chronic-obstructive-pulmonary-disease-canada-2018.html#a1.1. Accessed on: September 18, 2020.
- FitzGerald JM, Lemiere C, Lougheed MD, et al. Recognition and management of severe asthma: A Canadian Thoracic Society position statement. Can J Respir Crit Care Sleep Med. 2017;1(4):199–221. doi:https://doi.org/10.1080/24745332.2017.1395250.
- Firoozi F, Lemière C, Beauchesne MF, et al. Development and validation of database indexes of asthma severity and control. Thorax. 2007;62(7):581–587. doi:https://doi.org/10.1136/thx.2006.061572.
- Ungar WJ, Chapman KR, Santos MT. Assessment of a Medication-Based Asthma Index for Population Research. Am J Respir Crit Care Med. 2002;165(2):190–194. doi:https://doi.org/10.1164/ajrccm.165.2.2102012.
- Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulmonary Medicine. 2009;9(1):24. doi:https://doi.org/10.1186/1471-2466-9-24.
- Canadian Lung Association, Asthma Control in Canada™ Survey, 2016. Available from: https://www.lung.ca/news/advocacy-tools/our-publications. Accessed on September 18, 2020.
- FitzGerald JM, Boulet LP, McIvor RA, et al. Asthma control in Canada remains suboptimal: the Reality of Asthma Control (TRAC) study. Can Respir J. 2006;13(5):253–259. doi:https://doi.org/10.1155/2006/753083.
- Ismaila AS, Sayani AP, Marin M, et al. Clinical, economic, and humanistic burden of asthma in Canada: a systematic review. BMC Pulm Med. 2013;13(1):70. doi:https://doi.org/10.1186/1471-2466-13-70.
- To T, Simatovic J, Zhu J, et al. Asthma Deaths in a Large Provincial Health System. A 10-Year Population-Based Study. Ann Am Thorac Soc. 2014;11(8):1210–1217. doi:https://doi.org/10.1513/AnnalsATS.201404-138OC.
- Royal College of Physicians. Why asthma still kills: the National Review of Asthma Deaths (NRAD) Confidential Enquiry report. 2014. Available from: https://www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills. Accessed on September 18, 2020.
- Lougheed MD, Lemière C, Dell SD, et al. Canadian Thoracic Society Asthma Management Continuum–2010 Consensus Summary for children six years of age and over, and adults. Can Respir J. 2010;17(1):15–24. doi:https://doi.org/10.1155/2010/827281.
- Lougheed MD, Lemiere C, Ducharme FM, et al. Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Can Respir J. 2012;19(2):127–164. doi:https://doi.org/10.1155/2012/635624.
- Bateman ED, Harrison TW, Quirce S, et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res. 2011;12(1):38. doi:https://doi.org/10.1186/1465-9921-12-38.
- Bender BG, Pedan A, Varasteh LT. Adherence and persistence with fluticasone propionate/salmeterol combination therapy. J Allergy Clin Immunol. 2006;118(4):899–904. doi:https://doi.org/10.1016/j.jaci.2006.07.002.
- Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–928. doi:https://doi.org/10.1016/S0140-6736(19)31948-8.
- Bibi HS, Feigenbaum D, Hessen M, et al. Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Respir Med. 2006;100(3):458–462. doi:https://doi.org/10.1016/j.rmed.2005.06.011.
- Lange P, Scharling H, Ulrik CS, et al. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax. 2006;61(2):100–104. doi:https://doi.org/10.1136/thx.2004.037978.
- Ducharme FM, Dell SD, Radhakrishnan D, et al. Diagnosis and Management of Asthma in Preschoolers: A Canadian Thoracic Society and Canadian Paediatric Society Position Paper. Can Respir J. 2015;22:101572.
- Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182(18):E839–842. doi:https://doi.org/10.1503/cmaj.090449.
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. Available from: www.ginasthma.org. Accessed on September 18, 2020.
- National Heart, Lung, and Blood Institute. Advisory Council Asthma Expert Working Group. Guidelines for the Diagnosis and Management of Asthma (EPR-3). 2007. Available from: https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma. Accessed on September 18, 2020.
- British Thoracic Society/Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. 2019. Available from: https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/. Accessed on September 18, 2020.
- Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed.). 2011;343:d5928. doi:https://doi.org/10.1136/bmj.d5928.
- Diekemper R, Ireland B, Merz L. Development of the Documentation and Appraisal Review Tool (Dart) For Systematic Reviews. BMJ Quality & Safety. 2013;22(Suppl 1):61–62. doi:https://doi.org/10.1136/bmjqs-2013-002293.184.
- Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394. doi:https://doi.org/10.1016/j.jclinepi.2010.04.026.
- Alonso-Coello P, Schünemann HJ, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ (Clinical research ed.). 2016;353:i2016.
- Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ (Clinical research ed.). 2004;328(7454):1490.
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed.). 2008;336(7650):924–926.
- Gupta S, Rai N, Bhattacharrya O, et al. Optimizing the language and format of guidelines to improve guideline uptake. CMAJ. 2016;188(14):E362–e368. doi:https://doi.org/10.1503/cmaj.151102.
- Hargreave FE, Dolovich J, Newhouse MT. The assessment and treatment of asthma: a conference report. J Allergy Clin Immunol. 1990;85(6):1098–1111. doi:https://doi.org/10.1016/0091-6749(90)90056-a.
- FitzGerald JM, Spier S, Ernst P. Evidence-Based Asthma Guidelines. CHEST. 1996;110(6):1382–1383. doi:https://doi.org/10.1378/chest.110.6.1382.
- Boulet LP, Becker A, Bérubé D, et al. Canadian asthma consensus report, 1999. CMAJ. 1999;161(11 suppl 1):S1–S5.
- Dostaler SM, Olajos-Clow JG, Sands TW, et al. Comparison of Asthma Control Criteria: Importance of Spirometry. J Asthma. 2011;48(10):1069–1075. doi:https://doi.org/10.3109/02770903.2011.631243.
- Bateman ED, Reddel HK, O’Byrne PM, et al. As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma. NEJM. 2018;378(20):1877–1887. doi:https://doi.org/10.1056/NEJMoa1715275.
- Fitzpatrick AM, Jackson DJ, Mauger DT, et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol. 2016;138(6):1608–1618.e1612.
- Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9766):650–657. doi:https://doi.org/10.1016/S0140-6736(10)62145-9.
- O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma. NEJM. 2018;378(20):1865–1876. doi:https://doi.org/10.1056/NEJMoa1715274.
- Papi A, Canonica GW, Maestrelli P, et al. Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma. NEJM. 2007;356(20):2040–2052. doi:https://doi.org/10.1056/NEJMoa063861.
- Bateman ED, Boushey HA, Bousquet J, et al. Can Guideline-defined Asthma Control Be Achieved? Am J Respir Crit Care Med. 2004;170(8):836–844. doi:https://doi.org/10.1164/rccm.200401-033OC.
- Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210–1216. doi:https://doi.org/10.1016/j.jaci.2009.09.021.
- Lemanske RF, Mauger DT, Sorkness CA, et al. Step-up Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids. NEJM. 2010;362(11):975–985. doi:https://doi.org/10.1056/NEJMoa1001278.
- Busse WW, Shah SR, Somerville L, et al. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. J Allergy Clin Immunol. 2008;121(6):1407–1414, e1401-1406.
- Lazarus SC, Krishnan JA, King TS, et al. Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. NEJM. 2019;380(21):2009–2019. doi:https://doi.org/10.1056/NEJMoa1814917.
- Beasley R, Holliday M, Reddel HK, et al. Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma. NEJM. 2019;380(21):2020–2030. doi:https://doi.org/10.1056/NEJMoa1901963.
- Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361(9363):1071–1076. doi:https://doi.org/10.1016/S0140-6736(03)12891-7.
- Dusser D, Montani D, Chanez P, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62(6):591–604. doi:https://doi.org/10.1111/j.1398-9995.2007.01394.x.
- Buelo A, McLean S, Julious S, et al. At-risk children with asthma (ARC): a systematic review. Thorax. 2018;73(9):813. doi:https://doi.org/10.1136/thoraxjnl-2017-210939.
- Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4):1901872. doi:https://doi.org/10.1183/13993003.01872-2019.
- Bayly JE, Bernat D, Porter L, et al. Secondhand Exposure to Aerosols From Electronic Nicotine Delivery Systems and Asthma Exacerbations Among Youth With Asthma. Chest. 2019;155(1):88–93. doi:https://doi.org/10.1016/j.chest.2018.10.005.
- National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Review of the Health Effects of Electronic Nicotine Delivery Systems. Public Health Consequences of E-Cigarettes. Eaton DL, Kwan LY, Stratton K, editors. Washington (DC): National Academies Press (US). 2018.
- To T, Zhu J, Williams DP, et al. Frequency of health service use in the year prior to asthma death. J Asthma. 2016;53(5):505–509. doi:https://doi.org/10.3109/02770903.2015.1064949.
- Lazarinis N, Jørgensen L, Ekström T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax. 2014;69(2):130–136. doi:https://doi.org/10.1136/thoraxjnl-2013-203557.
- Papi A, Nicolini G, Baraldi E, et al. Regular vs prn nebulized treatment in wheeze preschool children. Allergy. 2009;64(10):1463–1471. doi:https://doi.org/10.1111/j.1398-9995.2009.02134.x.
- Reddel HK, Busse WW, Pedersen S, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017;389(10065):157–166. doi:https://doi.org/10.1016/S0140-6736(16)31399-X.
- Agertoft L, Pedersen S. Effect of Long-Term Treatment with Inhaled Budesonide on Adult Height in Children with Asthma. NEJM. 2000;343(15):1064–1069. doi:https://doi.org/10.1056/NEJM200010123431502.
- Kelly HW, Sternberg AL, Lescher R, et al. Effect of Inhaled Glucocorticoids in Childhood on Adult Height. NEJM. 2012;367(10):904–912. doi:https://doi.org/10.1056/NEJMoa1203229.
- Baggott C, Hardy J, Sparks J, et al. Self-titration of inhaled corticosteroid and β(2)-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial. Eur Respir J. 2020;56(4). doi:https://doi.org/10.1183/13993003.00170-2020.
- Calhoun WJ, Ameredes BT, King TS, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA. 2012;308(10):987–997. doi:https://doi.org/10.1001/2012.jama.10893.
- Chong J, Haran C, Chauhan BF, et al. Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults. Cochrane Database Syst Rev. 2015(7):Cd011032.
- Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics. 2009;123(3):e519-525. doi:https://doi.org/10.1542/peds.2008-2867.
- Ducharme FM, Tse SM, Chauhan B. Diagnosis, management, and prognosis of preschool wheeze. Lancet. 2014;383(9928):1593–1604. doi:https://doi.org/10.1016/S0140-6736(14)60615-2.
- Adams NP, Bestall JC, Jones P. Budesonide versus placebo for chronic asthma in children and adults. Cochrane Database Syst Rev. 1999(4): 1465–1858.
- Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev. 2008;(4):CD003135.
- Adams NP, Bestall JC, Malouf R, Lasserson TJ, Jones P. Beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev. 2005;(1):CD002738.
- Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev. 2008;2008(2):CD006217.
- Jackson DJ, Bacharier LB, Mauger DT, et al. Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations. NEJM. 2018;378(10):891–901. doi:https://doi.org/10.1056/NEJMoa1710988.
- Bacharier LB, Phillips BR, Zeiger RS, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol. 2008;122(6):1127–1135.e1128.
- Connett G, Lenney W. Prevention of viral induced asthma attacks using inhaled budesonide. Arch Dis Child. 1993;68(1):85–87. doi:https://doi.org/10.1136/adc.68.1.85.
- Ducharme FM, Lemire C, Noya FJ, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. NEJM. 2009;360(4):339–353. doi:https://doi.org/10.1056/NEJMoa0808907.
- Svedmyr J, Nyberg E, Thunqvist P, et al. Prophylactic intermittent treatment with inhaled corticosteroids of asthma exacerbations due to airway infections in toddlers. Acta Paediatr. 1999;88(1):42–47. doi:https://doi.org/10.1111/j.1651-2227.1999.tb01266.x.
- Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Arch Dis Child 1990;(65):407–410. doi:https://doi.org/10.1136/adc.65.4.407.
- Lougheed MD, Taite A, ten Hove J, et al. Pan-Canadian asthma and COPD standards for electronic health records: A Canadian Thoracic Society Expert Working Group Report. Can J Respir Crit Care Sleep Med. 2018;2(4):244–250. doi:https://doi.org/10.1080/24745332.2018.1517623.
- Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV1 is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol. 2001;107(1):61–67. doi:https://doi.org/10.1067/mai.2001.111590.
- Schatz M, Cook EF, Joshua A, et al. Risk factors for asthma hospitalizations in a managed care organization: development of a clinical prediction rule. Am J Manag Care. 2003;9(8):538–547.
- Tanaka A, Uno T, Sato H, et al. Predicting future risk of exacerbations in Japanese patients with adult asthma: A prospective 1-year follow up study. Allergol Int. 2017;66(4):568–573. doi:https://doi.org/10.1016/j.alit.2017.02.013.
- Stanford RH, Shah MB, D'Souza AO, et al. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403–407. doi:https://doi.org/10.1016/j.anai.2012.08.014.
- Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994;149(3 Pt 1):604–610. doi:https://doi.org/10.1164/ajrccm.149.3.8118625.
- Bloom CI, Nissen F, Douglas IJ, et al. Exacerbation risk and characterisation of the UK’s asthma population from infants to old age. Thorax. 2018;73(4):313–320. doi:https://doi.org/10.1136/thoraxjnl-2017-210650.